| You
are here: Home: BCU 5|2001: Section 4
GYNECOLOGIC ONCOLOGY GROUP (GOG) Web
link
The Gynecologic Oncology Group (GOG) is a national organization
dedicated to clinical research in the field of gynecologic cancers
including cancers that arise from the ovaries, uterus, cervix, vagina
and vulva. Its aim is to improve the treatment of gynecologic cancer
through research encompassing surgery, radiation therapy, chemotherapy,
pathology, immunology and/or gynecologic nursing. GOG consists of
over 60 “parent ” institutions, medical schools, colleges
and universities and more than 125 affiliated hospitals. There are
approximately 45 clinical trials active at any given time.
Contact Information
GOG Statistical and Data Center
Roswell Park Cancer Institute
Elm & Carlton Streets
Buffalo, NY 14263-0001
Phone:(716) 845-5702
GOG Administrative Office
1234 Market Street, Suite 1945
Philadelphia, PA 19107
Phone:(215) 854-0770
NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP (NCIC)
Web link
The National Cancer Institute of Canada Clinical Trials Group (NCIC
CTG) is a cooperative group that conducts clinical trials in cancer
therapy and supportive care throughout Canada and internationally.
The organization aims to undertake and support research that will
lead to reduction in the incidence of and morbidity and mortality
from cancer.NCIC established the clinical trials program in 1971
in response to investigators interested in carrying out multicenter
trials in Hodgkin’s disease and hypernephroma. The Investigational
New Drug (IND) program was established in 1982 and now conducts
phase I and II trials with cytotoxics and biologics.New agents from
the NCI (US) as well as the pharmaceutical industry are studied.
Open Breast Cancer Protocols
CAN-NCIC-MA20
Phase III Randomized Study of Adjuvant Breast Radiotherapy with
or without Regional Radiotherapy in Women with Resected,Early Stage,Invasive
Breast Cancer Protocol
CAN-NCIC-MA21; AMGEN-CAN-NCIC-MA21; BMS-CAN-NCIC-MA21; JANSSEN-CAN-NCIC-MA21;
P-UPJOHN-CAN-NCIC-MA21
Phase III Randomized Study of Adjuvant Cyclophosphamide, Epirubicin
and Fluorouracil Versus Cyclophosphamide, Epirubicin, Filgrastim
(G-CSF) and Epoetin Alfa Followed by Paclitaxel Versus Cyclophosphamide
and Doxorubicin Followed by Paclitaxel in Premenopausal or Early
Postmenopausal Women with Previously Resected Node-Positive or High-Risk
Node-Negative Stage I-IIIA Breast Cancer Protocol
CAN-NCIC-MA17; CLB-49805; EORTC-10983; JRF-Vor-Int-10; NCCTG-CAN-MA17;
SWOG-CAN-MA17
Phase III Randomized Study of Letrozole Versus Placebo in Women
with Primary Breast Cancer Who Have Completed at Least Five Years
of Adjuvant Tamoxifen Protocol
Contact Information
Central Office Staff
Queens University
82-84 Barrie Street
Kingston, Ontario
Phone:(613) 533-6430
Dr.Joseph L Pater, Group Director
E-mail:jpater@ctg.queensu.ca
NORTH CENTRAL CANCER TREATMENT GROUP (NCCTG) Web
link
The North Central Cancer Treatment Group (NCCTG) conducts clinical
trials in the treatment of a wide variety of cancers, as well as
studies in the control and prevention of cancer. NCCTG is comprised
of approximately 20 community clinics consisting of over 700 physicians
and 375 allied-health professionals. Based at the Mayo Cancer Center
in Rochester, MN, NCCTG affiliates are located in 11 states and
one Canadian province.
Open Breast Cancer Protocols
NCCTG-963255
Phase II Randomized Study of Irinotecan for Refractory Metastatic
Breast Cancer Protocol
NCCTG-983252
Phase II Randomized Study of Paclitaxel,Carboplatin and Trastuzumab
(Herceptin) as First-Line Chemotherapy in Women with Overexpressed
HER2, Metastatic Breast Cancer Protocol
NCCTG-N9932
Phase II Study of Docetaxel and Carboplatin as First-Line Therapy
in Patients with Metastatic Adenocarcinoma of the Breast Protocol
NCCTG-N0032
Phase II Study of Fulvestrant (ICI 182780) in Women with Metastatic
Breast Cancer Who Have Failed Aromatase Inhibitor Therapy Protocol
NCCTG-N003A
Phase II Study of Oral Vinorelbine in Elderly Women with Stage IV
Breast Cancer Protocol
NCCTG-N0031
Phase II Study of Topical Ceramide Cream in Women with Cutaneous
Breast Cancer Protocol
NCCTG-N9831;GUMC-00224
Phase III Randomized Study of Doxorubicin Plus Cyclophosphamide
Followed by Paclitaxel with or without Trastuzumab (Herceptin) in
Patients with HER2 Overexpressing Breast Cancer Protocol
NCCTG-979253;NCI-P98-0133
Phase III Randomized Study of Epoetin Alfa in Anemic Patients with
Advanced Cancer Undergoing Chemotherapy Protocol
CAN-NCIC-MA17; CLB-49805; EORTC-10983; JRF-Vor-Int-10; NCCTG-CAN-MA17;
SWOG-CAN-MA17
Phase III Randomized Study of Letrozole Versus Placebo in Women
with Primary Breast Cancer Who Have Completed at Least Five Years
of Adjuvant Tamoxifen Protocol
NCCTG-N9431
Correlation of Menstrual Cycle Phase at the Time of Surgery with
Disease- Free Survival in Women with Stage I/II Breast Cancer Protocol
Contact Information
NCCTG Operations Office
Plummer Building
200 1st Street, SW
Rochester, MN 55905
Fax: (507) 284-1902
E-mail: ncctg@mayo.edu
Page
5 of 6
Previous Page | Next
page
|
